MoCRA Serious Adverse Event Reporting: A Complete Compliance Guide for Cosmetic Brands Selling in the United States

A single customer complaint can become a regulatory issue much faster than many cosmetic brands realize. Under the Modernization of Cosmetics Regulation Act (MoCRA), companies marketing cosmetic products in the United States must carefully evaluate complaints and determine whether they qualify as serious adverse events requiring FDA reporting.

For cosmetic manufacturers, private label brands, importers, distributors, and international companies entering the U.S. market, understanding adverse event reporting obligations is no longer optional. MoCRA has significantly expanded FDA oversight of cosmetic products and introduced new compliance responsibilities that can directly impact market access and regulatory risk.

Why MoCRA Matters for Cosmetic Companies

MoCRA represents the most significant update to U.S. cosmetic regulation in decades. The legislation expanded FDA authority over cosmetic safety, facility registration, product listing, recordkeeping, and adverse event reporting.

As a result, complaints that were previously handled solely as customer service matters may now require formal regulatory evaluation and reporting.

Companies must establish systems capable of identifying, documenting, investigating, and escalating potential safety concerns in a timely manner.

What Is a Serious Adverse Event Under MoCRA?

A serious adverse event generally includes outcomes such as:

• Hospitalization

• Life-threatening reactions

• Serious infections

• Significant disability

• Permanent disfigurement

• Congenital anomalies or birth defects

• Medical intervention required to prevent permanent impairment

The seriousness of the outcome—not simply the existence of a complaint—determines whether reporting obligations may apply.

Examples of Potentially Reportable Events

The following examples may trigger reporting obligations:

• A facial serum causes severe burns requiring specialist treatment

• A shampoo results in significant hair loss requiring medical intervention

• A contaminated eye cosmetic causes an infection requiring hospitalization

• A cosmetic product triggers a severe allergic reaction requiring emergency medical care

Each complaint should be evaluated individually based on available evidence and outcome severity.

Understanding the 15-Business-Day Reporting Requirement

One of the most important MoCRA obligations is the reporting timeline.

Once the Responsible Person becomes aware of a reportable serious adverse event, FDA generally expects notification within 15 business days.

Many organizations fail to meet this requirement because complaints are not escalated quickly enough from customer service teams to regulatory or quality personnel.

Establishing clear internal escalation procedures is therefore critical.

Who Is the Responsible Person?

Under MoCRA, the Responsible Person is generally the manufacturer, packer, or distributor whose name appears on the cosmetic product label.

The Responsible Person is responsible for:

• Complaint evaluation

• Recordkeeping

• Adverse event reporting

• Investigation activities

• Follow-up communications

Companies should clearly define these responsibilities within their quality and regulatory systems.

Information Companies Should Collect

When investigating complaints, organizations should gather as much information as possible, including:

• Product name

• Batch or lot number

• Purchase information

• Description of the event

• Medical information when available

• Photographs

• Consumer contact information

• Investigation findings

Maintaining complete records helps support compliance and inspection readiness.

Five Common MoCRA Compliance Mistakes

Many cosmetic companies encounter compliance challenges due to avoidable mistakes.

Treating Complaints as Customer Service Issues Only
Complaint management should involve regulatory and quality personnel when potential safety concerns are identified.

Lack of Complaint Handling SOPs
Organizations should maintain documented procedures for complaint intake, escalation, investigation, and reporting.

Inadequate Documentation
Incomplete records can create compliance risks during FDA inspections.

Failure to Train Customer-Facing Teams
Employees handling complaints should understand how to identify potential serious adverse events.

Missing Reporting Deadlines
Failure to meet the 15-business-day reporting timeline can increase regulatory risk.

Building an Effective Complaint Handling System
An effective complaint management program should include:

• Complaint intake forms
• Escalation criteria
• Investigation procedures
• Record retention policies
• Management review processes
• Trend analysis activities

Staff training is equally important to ensure complaints are assessed consistently and escalated appropriately.

Serious vs Non-Serious Complaints
Not all complaints require FDA reporting.

Examples of non-serious complaints may include:

• Dissatisfaction with fragrance

• Product color concerns

• Packaging defects

• Temporary mild irritation

Potentially serious complaints may include:

• Hospitalization

• Severe allergic reactions

• Permanent scarring

• Significant hair loss

• Serious infections
Proper evaluation is necessary to determine whether reporting obligations apply.

Special Considerations for International Cosmetic Brands

Foreign cosmetic manufacturers often face communication challenges between manufacturers, importers, distributors, and U.S. representatives.

Maintaining visibility over complaints received in the U.S. market and establishing clear reporting pathways is essential for compliance.

Companies should ensure complaint information can be rapidly shared across all parties responsible for regulatory compliance.

FDA Inspection Readiness and Complaint Records

FDA now has expanded authority under MoCRA to review certain records related to cosmetic safety and adverse events.

Companies should maintain:

• Complaint logs

• Investigation records

• SOPs

• Employee training records

• Corrective action documentation

Strong documentation practices support inspection readiness and demonstrate a commitment to consumer safety.

How Fiducia Globus Supports MoCRA Compliance

Fiducia Globus supports cosmetic companies through:

• U.S. Responsible Person services
• MoCRA compliance programs
• Facility registration support
• Cosmetic product listing services
• Complaint handling procedure development
• Regulatory documentation reviews
• Ongoing compliance support

Whether you are a manufacturer, importer, private label brand, or distributor, our team helps navigate FDA cosmetic requirements and develop sustainable compliance systems.

Conclusion

MoCRA has fundamentally changed cosmetic compliance expectations in the United States.

Companies that establish robust complaint handling procedures, understand serious adverse event reporting obligations, and maintain strong documentation systems will be better positioned to protect consumers and maintain uninterrupted access to the U.S. market.

A single complaint can quickly become a compliance issue. The organizations that prepare today will be the ones best positioned for long-term success tomorrow.